Date Log
Submitted
July 31, 2020
Published
July 31, 2020
Novel treatments for asthma: Corticosteroids and other anti-inflammatory agents.
Corresponding Author(s) : Ahmed Abdalla
a_abdallah1983@hotmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 2 No. 2 (2014): 2014 Volume 2- Issue -2
Abstract
Asthma management is a challenge due to the prevalence of disease in the world. Based on the immunological and inflammatory mechanisms of asthma, corticosteroids and anti-inflammatory participate greatly in the treatment plan. Due to different reasons, there is still an unmet need to develop new agents in this field. A lot of compounds with anti-inflammatory effect are investigated in both pre-clinical and clinical studies.
Keywords
asthma
corticosteroids
anti-inflammatory
Ahmed Abdalla. (2020). Novel treatments for asthma: Corticosteroids and other anti-inflammatory agents. International Journal of Allied Medical Sciences and Clinical Research, 2(2), 151–153. https://doi.org/10.61096/ijamscr.v2.iss2.2014.151-153
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
[1] Heaney lg and robinson ds. Severe asthma treatment: need for characterising patients. Lancet. 2005, 365(9463):974-6.
[2] Barnes pj. New therapies for asthma. Trends in molecular medicine. 2006, 12(11):515-9.
[3] Townley rg and suliaman f. The mechanism of corticosteroids in treating asthma. Ann allergy. 1987, 58(1):1-6.
[4] Dennis l. And spangler. The role of inhaled corticosteroids in asthma treatment: a health economic perspective. Am j manag care. 2012;18:s35-s39.
[5] Dunlap ne and fulmer jd. Corticosteroid therapy in asthma. Clin chest med. 1984, 5(4):669-83.
[6] Reynolds na and scott lj. Ciclesonide. Drugs. 2004; 64(5):511-9.
[7] Barnes pj. How corticosteroids control inflammation. Br. J. Pharmacol. 2006; 148(3), 245–254.
[8] Catley m. Dissociated steroids. Scientificworldjournal. 2007; 7:421-30.
[9] Doggrell s. Is al-438 likely to have fewer side effects than the glucocorticoids?
[10] 2003; 12(7):1227-9. (doi:10.1517/13543784.12.7.1227).
[11] Hermkens p, kamp s, lusher s and veeneman g. Non-steroidal steroid receptor modulators. Idrugs 2006; 9(7):488-494.
[12] Loke tk, sousa ar, corrigan cj and lee th. Glucocorticoid-resistant asthma. Curr allergy asthma rep. 2002; 2(2):144-50.
[13] Wang d and cui x. Evaluation of pde4 inhibition for copd. Int j chron obstruct pulmon dis. 2006; 1(4): 373-9.
[14] Field sk. Roflumilast: an oral, once-daily selective pde-4 inhibitor for the management of copd and asthma. Expert opin investig drugs. 2008; 17(5):811-8.
[15] Giembycz ma. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert opin investig drugs. 2001; 10(7):1361-79.
References
[1] Heaney lg and robinson ds. Severe asthma treatment: need for characterising patients. Lancet. 2005, 365(9463):974-6.
[2] Barnes pj. New therapies for asthma. Trends in molecular medicine. 2006, 12(11):515-9.
[3] Townley rg and suliaman f. The mechanism of corticosteroids in treating asthma. Ann allergy. 1987, 58(1):1-6.
[4] Dennis l. And spangler. The role of inhaled corticosteroids in asthma treatment: a health economic perspective. Am j manag care. 2012;18:s35-s39.
[5] Dunlap ne and fulmer jd. Corticosteroid therapy in asthma. Clin chest med. 1984, 5(4):669-83.
[6] Reynolds na and scott lj. Ciclesonide. Drugs. 2004; 64(5):511-9.
[7] Barnes pj. How corticosteroids control inflammation. Br. J. Pharmacol. 2006; 148(3), 245–254.
[8] Catley m. Dissociated steroids. Scientificworldjournal. 2007; 7:421-30.
[9] Doggrell s. Is al-438 likely to have fewer side effects than the glucocorticoids?
[10] 2003; 12(7):1227-9. (doi:10.1517/13543784.12.7.1227).
[11] Hermkens p, kamp s, lusher s and veeneman g. Non-steroidal steroid receptor modulators. Idrugs 2006; 9(7):488-494.
[12] Loke tk, sousa ar, corrigan cj and lee th. Glucocorticoid-resistant asthma. Curr allergy asthma rep. 2002; 2(2):144-50.
[13] Wang d and cui x. Evaluation of pde4 inhibition for copd. Int j chron obstruct pulmon dis. 2006; 1(4): 373-9.
[14] Field sk. Roflumilast: an oral, once-daily selective pde-4 inhibitor for the management of copd and asthma. Expert opin investig drugs. 2008; 17(5):811-8.
[15] Giembycz ma. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert opin investig drugs. 2001; 10(7):1361-79.
[2] Barnes pj. New therapies for asthma. Trends in molecular medicine. 2006, 12(11):515-9.
[3] Townley rg and suliaman f. The mechanism of corticosteroids in treating asthma. Ann allergy. 1987, 58(1):1-6.
[4] Dennis l. And spangler. The role of inhaled corticosteroids in asthma treatment: a health economic perspective. Am j manag care. 2012;18:s35-s39.
[5] Dunlap ne and fulmer jd. Corticosteroid therapy in asthma. Clin chest med. 1984, 5(4):669-83.
[6] Reynolds na and scott lj. Ciclesonide. Drugs. 2004; 64(5):511-9.
[7] Barnes pj. How corticosteroids control inflammation. Br. J. Pharmacol. 2006; 148(3), 245–254.
[8] Catley m. Dissociated steroids. Scientificworldjournal. 2007; 7:421-30.
[9] Doggrell s. Is al-438 likely to have fewer side effects than the glucocorticoids?
[10] 2003; 12(7):1227-9. (doi:10.1517/13543784.12.7.1227).
[11] Hermkens p, kamp s, lusher s and veeneman g. Non-steroidal steroid receptor modulators. Idrugs 2006; 9(7):488-494.
[12] Loke tk, sousa ar, corrigan cj and lee th. Glucocorticoid-resistant asthma. Curr allergy asthma rep. 2002; 2(2):144-50.
[13] Wang d and cui x. Evaluation of pde4 inhibition for copd. Int j chron obstruct pulmon dis. 2006; 1(4): 373-9.
[14] Field sk. Roflumilast: an oral, once-daily selective pde-4 inhibitor for the management of copd and asthma. Expert opin investig drugs. 2008; 17(5):811-8.
[15] Giembycz ma. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert opin investig drugs. 2001; 10(7):1361-79.
